Association of Cohort and Individual Substance Use With Risk of Transitioning to Drug Use, Drug Use Disorder, and Remission From Disorder: Findings From the World Mental Health Surveys.


Journal

JAMA psychiatry
ISSN: 2168-6238
Titre abrégé: JAMA Psychiatry
Pays: United States
ID NLM: 101589550

Informations de publication

Date de publication:
01 07 2019
Historique:
pubmed: 14 3 2019
medline: 17 6 2020
entrez: 14 3 2019
Statut: ppublish

Résumé

Limited empirical research has examined the extent to which cohort-level prevalence of substance use is associated with the onset of drug use and transitioning into greater involvement with drug use. To use cross-national data to examine time-space variation in cohort-level drug use to assess its associations with onset and transitions across stages of drug use, abuse, dependence, and remission. The World Health Organization World Mental Health Surveys carried out cross-sectional general population surveys in 25 countries using a consistent research protocol and assessment instrument. Adults from representative household samples were interviewed face-to-face in the community in relation to drug use disorders. The surveys were conducted between 2001 and 2015. Data analysis was performed from July 2017 to July 2018. Data on timing of onset of lifetime drug use, DSM-IV drug use disorders, and remission from these disorders was assessed using the Composite International Diagnostic Interview. Associations of cohort-level alcohol prevalence and drug use prevalence were examined as factors associated with these transitions. Among the 90 027 respondents (48.1% [SE, 0.2%] men; mean [SE] age, 42.1 [0.1] years), 1 in 4 (24.8% [SE, 0.2%]) reported either illicit drug use or extramedical use of prescription drugs at some point in their lifetime, but with substantial time-space variation in this prevalence. Among users, 9.1% (SE, 0.2%) met lifetime criteria for abuse, and 5.0% (SE, 0.2%) met criteria for dependence. Individuals who used 2 or more drugs had an increased risk of both abuse (odds ratio, 5.17 [95% CI, 4.66-5.73]; P < .001) and dependence (odds ratio, 5.99 [95% CI, 5.02-7.16]; P < .001) and reduced probability of remission from abuse (odds ratio, 0.86 [95% CI, 0.76-0.98]; P = .02). Birth cohort prevalence of drug use was also significantly associated with both initiation and illicit drug use transitions; for example, after controlling for individuals' experience of substance use and demographics, for each additional 10% of an individual's cohort using alcohol, a person's odds of initiating drug use increased by 28% (odds ratio, 1.28 [95% CI, 1.26-1.31]). Each 10% increase in a cohort's use of drug increased individual risk by 12% (1.12 [95% CI, 1.11-1.14]). Birth cohort substance use is associated with drug use involvement beyond the outcomes of individual histories of alcohol and other drug use. This has important implications for understanding pathways into and out of problematic drug use.

Identifiants

pubmed: 30865282
pii: 2727386
doi: 10.1001/jamapsychiatry.2019.0163
pmc: PMC6583659
mid: NIHMS1037297
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

708-720

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA044170
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH070884
Pays : United States
Organisme : NIMH NIH HHS
ID : R13 MH066849
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH069864
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA016558
Pays : United States
Organisme : FIC NIH HHS
ID : R03 TW006481
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH059575
Pays : United States

Commentaires et corrections

Type : ErratumIn

Références

Subst Use Misuse. 2000 May-Jun;35(6-8):925-48
pubmed: 10847217
Alcohol Clin Exp Res. 2003 Jan;27(1):93-9
pubmed: 12544012
Br J Psychiatry. 2003 Apr;182:330-6
pubmed: 12668409
Biol Psychiatry. 2004 Jan 1;55(1):69-76
pubmed: 14706427
Int J Methods Psychiatr Res. 2004;13(2):93-121
pubmed: 15297906
Arch Gen Psychiatry. 2004 Sep;61(9):891-6
pubmed: 15351767
Int J Methods Psychiatr Res. 2005;14(3):119-29
pubmed: 16389888
Addict Behav. 2006 Jun;31(6):962-83
pubmed: 16677774
Int J Methods Psychiatr Res. 2006;15(4):167-80
pubmed: 17266013
Alcohol Clin Exp Res. 2008 May;32(5):763-70
pubmed: 18336633
Drug Alcohol Depend. 2009 Jan 1;99(1-3):68-78
pubmed: 18768267
Addiction. 2009 Jan;104(1):27-37
pubmed: 19133886
Addiction. 2009 Aug;104(8):1313-23
pubmed: 19438840
Compr Psychiatry. 2009 Jul-Aug;50(4):299-306
pubmed: 19486727
J Stud Alcohol Drugs. 2010 Sep;71(5):695-703
pubmed: 20731974
Drug Alcohol Depend. 2011 May 1;115(1-2):120-30
pubmed: 21145178
Alcohol Alcohol. 2011 May-Jun;46(3):324-32
pubmed: 21414952
Subst Use Misuse. 2011;46(9):1169-78
pubmed: 21417555
Addiction. 2011 Oct;106(10):1790-800
pubmed: 21545669
J Child Adolesc Subst Abuse. 2012 Sep 1;21(4):333-348
pubmed: 23284228
Am J Psychiatry. 2013 Jun;170(6):660-70
pubmed: 23511653
Am J Drug Alcohol Abuse. 2013 May;39(3):168-79
pubmed: 23721532
Alcohol Alcohol. 2014 Jan-Feb;49(1):103-8
pubmed: 23904251
Drug Alcohol Rev. 2014 Sep;33(5):555-64
pubmed: 25186194
Lancet Psychiatry. 2016 Mar;3(3):251-64
pubmed: 26905480
Lancet Psychiatry. 2016 Mar;3(3):265-79
pubmed: 26905482
Int J Methods Psychiatr Res. 2017 Sep;26(3):
pubmed: 28211594
Drug Alcohol Rev. 2018 May;37(4):546-556
pubmed: 29505682
Drug Alcohol Depend. 2018 Oct 1;191:145-151
pubmed: 30107320
J Nerv Ment Dis. 1988 Dec;176(12):719-25
pubmed: 3199107
Am J Public Health. 1988 Oct;78(10):1315-21
pubmed: 3421387
Arch Gen Psychiatry. 1994 Jan;51(1):8-19
pubmed: 8279933
J Subst Abuse. 1996;8(2):195-210
pubmed: 8880660
J Stud Alcohol. 1997 Sep;58(5):464-73
pubmed: 9273910

Auteurs

Louisa Degenhardt (L)

National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.

Chrianna Bharat (C)

National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.

Meyer D Glantz (MD)

Department of Epidemiology, Services, and Prevention Research, National Institute on Drug Abuse, National Institute of Health, Bethesda, Maryland.

Nancy A Sampson (NA)

Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.

Ali Al-Hamzawi (A)

College of Medicine, Al-Qadisiya University, Diwaniya Governorate, Iraq.

Jordi Alonso (J)

Health Services Research Unit, Institut Hospital del Mar Investigacions Mèdiques, Barcelona, Spain.
Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública, Barcelona, Spain.
Pompeu Fabra University, Barcelona, Spain.

Laura H Andrade (LH)

Section of Psychiatric Epidemiology-Laboratórios de Investigação Médica No. 23, Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.

Brendan Bunting (B)

School of Psychology, Ulster University, Londonderry, United Kingdom.

Alfredo Cia (A)

Anxiety Disorders Center, Buenos Aires, Argentina.

Giovanni de Girolamo (G)

IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.

Peter De Jonge (P)

Developmental Psychology, Department of Psychology, Rijksuniversiteit Groningen, Groningen, Netherlands.
Interdisciplinary Center Psychopathology and Emotion Regulation, Department of Psychiatry, University Medical Center Groningen, Groningen, Netherlands.

Koen Demyttenaere (K)

Department of Psychiatry, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium.

Oye Gureje (O)

Department of Psychiatry, University College Hospital, Ibadan, Nigeria.

Josep Maria Haro (JM)

Parc Sanitari Sant Joan de Déu, Centro de Investigación Biomédica en Red en Salud Mental, Universitat de Barcelona, Sant Boi de Llobregat, Barcelona, Spain.

Meredith G Harris (MG)

School of Public Health, The University of Queensland, Brisbane, Australia.
Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Brisbane, Australia.

Yanling He (Y)

Shanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.

Hristo Hinkov (H)

National Center of Public Health and Analyses, Sofia, Bulgaria.

Aimee Nasser Karam (AN)

Institute for Development, Research, Advocacy and Applied Care, Beirut, Lebanon.

Elie G Karam (EG)

Department of Psychiatry and Clinical Psychology, Faculty of Medicine, Balamand University, Beirut, Lebanon.
Department of Psychiatry and Clinical Psychology, St George Hospital University Medical Center, Beirut, Lebanon.
Institute for Development, Research, Advocacy and Applied Care, Beirut, Lebanon.

Andrzej Kiejna (A)

Wrocław Medical University, Wrocław, Poland.
University of Lower Silesia, Wrocław, Poland.

Viviane Kovess-Masfety (V)

Ecole des Hautes Etudes en Santé Publique, EA 4057, Paris Descartes University, Paris, France.

Victor Lasebikan (V)

Department of Psychiatry, College of Medicine, University of Ibadan, Nigeria.

Sing Lee (S)

Department of Psychiatry, Chinese University of Hong Kong, Tai Po, Hong Kong.

Daphna Levinson (D)

Mental Health Services, Ministry of Health, Jerusalem, Israel.

Maria Elena Medina-Mora (ME)

National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico City, Mexico.

Zeina Mneimneh (Z)

Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, Michigan.

Fernando Navarro-Mateu (F)

Unidad de Docencia, Investigación y Formación en Salud Mental, Servicio Murciano de Salud, Murcia, Spain.
Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca.
Centro de Investigación Biomédica en ERed en Epidemiología y Salud Pública, Murcia, Spain.

Marina Piazza (M)

Universidad Peruana Cayetano Heredia, Lima, Peru.

José Posada-Villa (J)

Colegio Mayor de Cundinamarca University, Faculty of Social Sciences, Bogota, Colombia.

Kate Scott (K)

Department of Psychological Medicine, University of Otago, Dunedin, New Zealand.

Dan J Stein (DJ)

South African Medical Council Research Unit on Risk and Resilience in Mental Disorders, Department of Psychiatry and Mental Health, Neuroscience Institute, University of Cape Town, Cape Town, South Africa.
Groote Schuur Hospital, Cape Town, South Africa.

Hisateru Tachimori (H)

National Institute of Mental Health, National Center for Neurology and Psychiatry, Kodaira, Tokyo, Japan.

Nathan Tintle (N)

Department of Mathematics, Statistics and Computer Science, Dordt College, Sioux Center, Iowa.

Yolanda Torres (Y)

Center for Excellence on Research in Mental Health, CES University, Medellín, Colombia.

Ronald C Kessler (RC)

Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH